Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial

References

• Brown RH, Al-Chalabi A. Jr. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162–72.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Liu D, Leitner ML, Schoenfeld D, Johns DR, Ferguson T, et al. Quantitative strength testing in ALS clinical trials. Neurology 2016;87:617–24.
   PubMed Web of Science ®Google Scholar
• Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, et al. Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis. JAMA Neurol. 2018;75:58–64.
   PubMed Web of Science ®Google Scholar
• Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:414–25.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, de Jongh AD, Nikolakopoulos S, McDermott CJ, Eijkemans MJC, Roes KCB, et al. An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:300–7.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Fitzpatrick R. Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5. J Neurol Neurosurg Psychiatry. 2001;70:70–3.
   PubMed Web of Science ®Google Scholar
• Hwee DT, Kennedy AR, Hartman JJ, Ryans J, Durham N, Malik FI, et al. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. J Pharmacol Exp Ther. 2015;353:159–68.
   PubMed Web of Science ®Google Scholar
• Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, et al. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2018;57:729–34.
   PubMed Web of Science ®Google Scholar
• Collibee SE, Bergnes G, Chuang C, Ashcraft L, Gardina J, Garard M, et al. Discovery of reldesemtiv, a fast skeletal muscle troponin activator for the treatment of impaired muscle function. J Med Chem. 2021;64:14930–41.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Andrews JA, Genge A, Jackson C, Lechtzin N, Miller TM, et al. A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:287–99.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research. Qualification process for drug development tools. Guidance for industry and FDA staff; November 2020. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-process-drug-development-tools-guidance-industry-and-fda-staff. Accessed August 14, 2023.
   Google Scholar
• Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919–30.
   PubMed Web of Science ®Google Scholar
• The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505–12.
   PubMed Web of Science ®Google Scholar
• Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099–110.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond). 2014;4:605–18.
   PubMedGoogle Scholar
• Hufnagel SB. Defining and assessing clinical benefit: a regulatory perspective. Presented at the FDA workshop "Developing therapies for primary mitochondrial diseases: bridging the gaps" held September 6, 2019; Silver Spring, MD, USA. Available at: https://www.fda.gov/media/131585/download. Accessed August 15, 2023.
   Google Scholar
• U.S. Food and Drug Administration. Clinical outcome assessment (COA): frequently asked questions 2020 (updated 2 December 2020). Available at: https://www.fda.gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions. Accessed August 14, 2023.
   Google Scholar
• U.S. Food and Drug Administration Center for Drug Evaluation and Research. Clinical outcome assessment (COA) compendium 2021 (updated June 2021). https://www.fda.gov/media/130138/download. Accessed August 14, 2023.
   Google Scholar
• Thakore NJ, Lapin BR, Pioro EP, Pooled Resource Open-Access ALS Clinical Trials Consortium. Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort. Muscle Nerve. 2018;57:937–45.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059–67.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al. A clinical trial of creatine in ALS. Neurology 2004;63:1656–61.
   PubMed Web of Science ®Google Scholar